おすすめの製品
品質水準
アッセイ
≥98% (HPLC)
フォーム
powder
色
white to beige
溶解性
DMSO: 10 mg/mL (clear solution; warmed)
保管温度
2-8°C
SMILES記法
CCN(CC)CCNc1ccc2ncn3-c4ccc(O)cc4C(=O)c1c23
InChI
1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
InChI Key
CUNDRHORZHFPLY-UHFFFAOYSA-N
遺伝子情報
human ... FLT3(2322) , TOP2A(7153) , TOP2B(7155)
生物化学的／生理学的作用
Symadex is a FLT3 and topoisomerase-II inhibitor; ABCG2 substrate; cell cycle modulator.
Symadex is an FMS-like tyrosine kinase 3 (FLT3) and topoisomerase-II inhibitor; ABCG2 substrate; cell cycle modulator.
特徴および利点
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the PDGFR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SML0465-25MG:
SML0465-BULK:
SML0465-5MG:
SML0465-VAR:
最新バージョンのいずれかを選択してください：
Magdalena Hyzy et al.
Biochemical pharmacology, 69(5), 801-809 (2005-02-16)
In this study, we investigated the cell death process induced by imidazoacridone C-1311 (Symadex) in HT-29 human colon carcinoma cells which have been shown to be preferentially sensitive to this compound in experimental tumour models both in vitro and in
Cinzia De Marco et al.
International journal of oncology, 31(4), 907-913 (2007-09-06)
The cytotoxic activity of the imidazoacridinone C1311 was related to its effect on cell cycle progression in 16 human cell lines from different solid tumour types and leukaemias. A 72-h exposure to C1311 induced a wide range of growth inhibition
Anna Skwarska et al.
Apoptosis : an international journal on programmed cell death, 12(12), 2245-2257 (2007-10-10)
Imidazoacridinone C-1311 is a DNA-targeting antitumor intercalator/alkylator currently undergoing Phase II clinical trials. Here, we elucidated the sequence of death responses to C-1311 in human leukemia MOLT4 cells using drug concentration (30 nM) that causes near complete cell growth inhibition
Zofia Mazerska et al.
Biochemical pharmacology, 66(9), 1727-1736 (2003-10-18)
The imidazoacridinone derivative, C-1311, is an antitumor agent that has been under phase I of clinical trial. The work presented here aims to elucidate the molecular mechanism of the enzymatic oxidative activation of this drug in such a model metabolic
Marie Suggitt et al.
International journal of oncology, 29(6), 1493-1499 (2006-11-08)
We describe a modified hollow fibre assay (HFA) for investigating the potential of novel molecules as pharmaceutical agents. In particular the assay provides drug/target interaction data that can facilitate the selection of lead compounds for further evaluation in more sophisticated
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）